Patents Assigned to C2N Diagnostics
  • Patent number: 12253529
    Abstract: The invention generally relates to methods for the diagnosis and treatment of neurological and neurodegenerative diseases, disorders, and associated processes. Specifically, the present invention is directed toward methods to determine prognosis, diagnosis or efficacy of a therapeutic regimen by using a detectable label to measure levels of alpha-synuclein.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: March 18, 2025
    Assignee: C2N Diagnostics
    Inventors: Tim West, Andrew C. Paoletti
  • Patent number: 10481167
    Abstract: The present invention provides methods for measuring the absolute concentration of a biomolecule of interest in a subject. Such biomolecules may be implicated in one or more neurological and neurodegenerative diseases or disorders. Also provided is a method for determining whether a therapeutic agent affects the in vivo metabolism of a central nervous system derived biomolecule. Also provided are kits for performing the methods of the invention.
    Type: Grant
    Filed: December 4, 2009
    Date of Patent: November 19, 2019
    Assignee: C2N Diagnostics
    Inventors: Tim West, Andrew Corey Paoletti
  • Patent number: 10261097
    Abstract: The invention generally relates to methods for the diagnosis and treatment of neurological and neurodegenerative diseases, disorders, and associated processes. Specifically, the present invention is directed toward methods to determine prognosis, diagnosis or efficacy of a therapeutic regimen by using a detectable label to measure levels of alpha-synuclein.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: April 16, 2019
    Assignee: C2N Diagnostics
    Inventors: Tim West, Andrew C. Paoletti
  • Publication number: 20140065636
    Abstract: The present invention provides methods for measuring the absolute concentration of a biomolecule of interest in a subject. Such biomolecules may be implicated in one or more neurological and neurodegenerative diseases or disorders. Also provided is a method for determining whether a therapeutic agent affects the in vivo metabolism of a central nervous system derived biomolecule. Also provided are kits for performing the methods of the invention.
    Type: Application
    Filed: August 15, 2013
    Publication date: March 6, 2014
    Applicant: C2N Diagnostics
    Inventors: Tim West, Andrew Corey Paoletti
  • Publication number: 20120015371
    Abstract: The present invention provides methods for measuring the absolute concentration of a biomolecule of interest in a subject. Such biomolecules may be implicated in one or more neurological and neurodegenerative diseases or disorders. Also provided is a method for determining whether a therapeutic agent affects the in vivo metabolism of a central nervous system derived biomolecule. Also provided are kits for performing the methods of the invention.
    Type: Application
    Filed: December 4, 2009
    Publication date: January 19, 2012
    Applicant: C2N Diagnostics
    Inventors: Tim West, Andrew Corey Paoletti